Benitec Biopharma
BNTC
25 hedge funds and large institutions have $2.09M invested in Benitec Biopharma in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
0% more funds holding
Funds holding: 25 → 25 (0)
1.04% less ownership
Funds ownership: 3.63% → 2.59% (-1%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
65% less capital invested
Capital invested by funds: $5.92M → $2.09M (-$3.82M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$58.4K |
| 2 |
Renaissance Technologies
New York
|
+$50.8K |
| 3 |
Walleye Capital
New York
|
+$30.6K |
| 4 |
VF
Virtu Financial
New York
|
+$16.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$578K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$479K |
| 3 |
ACM
Altium Capital Management
New York
|
-$245K |
| 4 |
CF
Cantor Fitzgerald
New York
|
-$21.7K |
| 5 |
Millennium Management
New York
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
26
Altium Capital Management
New York
| – | -$245K | -38,753 | Closed |
|
|
27
Millennium Management
New York
| – | -$19K | -3,070 | Closed |
|
28
Bank of New York Mellon
New York
| – | -$6K | -872 | Closed |
|
BNTC Hedge Fund Activity: Q4 2022 in Review
25 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2022, worth a combined $2.09M — down 65% from $5.92M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BNTC positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $58.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $578K sold.
- 25 institutional investors held Benitec Biopharma (BNTC) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $2.09M of Benitec Biopharma stock for Q4 2022, down 65% quarter-over-quarter.
- 7 funds opened new Benitec Biopharma positions in Q4 2022 and 6 closed out, a net change of +1 holder.
- The largest Benitec Biopharma buyer in Q4 2022 was Morgan Stanley, an estimated $58.4K added.
- The largest Benitec Biopharma seller in Q4 2022 was Armistice Capital, an estimated $578K sold.
Based on aggregated 13F filings for Q4 2022.